Amlodipine/Olmesartan — $0 on Listed Strengths

About Amlodipine/Olmesartan

Amlodipine olmesartan is a powerful combination medication prescribed to manage high blood pressure, a critical step in preventing serious health issues. At TheDrugClub, we believe essential medications shouldn't break the bank. High blood pressure, or hypertension, is a silent but serious condition that, if left untreated, can lead to severe health complications like heart attack, stroke, kidney disease, and vision problems. Amlodipine olmesartan is a widely prescribed medication designed to effectively manage this condition. ### What Amlodipine Olmesartan Treats

This medication is specifically used to treat high blood pressure in adults. It's often prescribed when a single medication isn't enough to bring blood pressure down to a healthy level. By lowering blood pressure, amlodipine olmesartan significantly reduces the risk of the aforementioned cardiovascular and renal complications, helping you maintain a healthier, longer life. ### How It Works

Amlodipine olmesartan is a combination of two distinct active ingredients, each working through a different mechanism to achieve comprehensive blood pressure control:

• Amlodipine: This component is a calcium channel blocker. It works by

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Amlodipine/Olmesartan is approved for (FDA label)

Amlodipine besylate and olmesartan medoxomil is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine besylate and olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Source: Read the full FDA label on DailyMed. Label effective date: April 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Amlodipine/Olmesartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus ( 5.1 , 8.1 ). WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue amlodipine besylate and olmesartan medoxomil as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Amlodipine/Olmesartan (FDA label)

Amlodipine besylate and olmesartan medoxomil tablets are formulated for oral administration in the following strength combinations: Amlodipine equivalent: 5/20 - 5mg; 5/40 - 5mg; 10/20 - 10mg; 10/40 - 10mg Olmesartan medoxomil: 5/20 - 20mg; 5/40 - 40mg; 10/20 - 20mg; 10/40 - 40mg Tablets: (amlodipine/olmesartan medoxomil content) 5/20 mg, 10/20 mg, 5/40 mg, and 10/40 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Amlodipine/Olmesartan (FDA label)

Most common adverse reaction (incidence ≥3%) is edema ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Amlodipine besylate and olmesartan medoxomil The data described below reflect exposure to amlodipine besylate and olmesartan medoxomil in more than 1600 patients including more than 1000 exposed for at least 6 months and more than 700 exposed for 1 year.

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Amlodipine/Olmesartan (FDA label)

Do not co-administer aliskiren with amlodipine besylate and olmesartan medoxomil in patients with diabetes [ see Drug Interactions ( 7.2 )] . Do not co-administer aliskiren with amlodipine besylate and olmesartan medoxomil in patients with diabetes ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Amlodipine/Olmesartan (FDA label)

Anticipate hypotension in volume- or salt-depleted patients with treatment initiation. Start treatment under close supervision ( 5.2 ). Increased angina or myocardial infarction may occur upon dosage initiation or increase ( 5.3 ). Impaired renal function: changes in renal function may occur ( 5.4 ). Sprue-like enteropathy has been reported. Consider discontinuation of amlodipine besylate and olmesartan medoxomil in cases where no other etiology is found ( 5.6 ). 5.1 Fetal Toxicity Amlodipine besylate and olmesartan medoxomil can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Amlodipine/Olmesartan (FDA label)

Amlodipine ( 7.1 ): If simvastatin is co-administered with amlodipine, do not exceed 20 mg daily of simvastatin. Increased exposure of cyclosporine and tacrolimus. Increased exposure of amlodipine when coadministered with CYP3A inhibitors. Olmesartan medoxomil ( 7.2 ): Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. Lithium: Increases in serum lithium concentrations and lithium toxicity. 7.1 Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily [see Clinical Pharmacology ( 12.3 )] . Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Source: FDA prescribing information (DailyMed). Set ID: 132cca8f-48a2-2516-e063-6394a90a5f32. SPL document ID: 508d4d92-abe0-6182-e063-6394a90a7bcc. Label effective date: April 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.